Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.48 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MLYCD | O95822 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14113481 | 1.00 | NPC1 (0.48) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL3301443 | 1.00 | NPC1 (0.48) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL3296853 | 0.91 | ALDH1A1 (0.52) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL3296857 | 0.91 | ALDH1A1 (0.52) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL14113694 | 0.91 | ALDH1A1 (0.52) | MAPTMEN1KMT2AALDH1A1LMNA | |
| SCHEMBL3307362 | 0.90 | LMNA (0.48) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL3307357 | 0.90 | LMNA (0.48) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL14113407 | 0.90 | LMNA (0.48) | NPC1RAB9AMAPTMEN1KMT2A | |
| SCHEMBL3299613 | 0.86 | NAMPT (0.49) | NPC1RAB9AMAPTKMT2AALDH1A1 | |
| SCHEMBL3299610 | 0.86 | NAMPT (0.49) | NPC1RAB9AMAPTKMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100093733-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | PROSIDION LIMITED (GB) | 2010-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093733-A1 | AMIDE AND UREA DERIVATIVES FOR THE TREATMENT OF METABOLIC DISEASES | CPS1, GOT2, GPR119 | NPC1 630/4885RAB9A 1908/4885MAPT 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.